Cargando…

Silymarin for the Prevention of Contrast-Induced Nephropathy: A Placebo-Controlled Clinical Trial

BACKGROUND: Silymarin is a flavonoid complex with nephro-protective properties. We evaluated the efficacy of silymarin in the prevention of contrast-induced nephropathy (CIN). METHODS: This placebo-controlled clinical trial was conducted on 143 patients with chronic stable angina referring for elect...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sedighifard, Zohreh, Roghani, Farshad, Bidram, Peyman, Harandi, Samaneh Aalami, Molavi, Safieh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4755255/ https://www.ncbi.nlm.nih.gov/pubmed/26941924 http://dx.doi.org/10.4103/2008-7802.174762

Ejemplares similares

Atorvastatin and prevention of contrast induced nephropathy following coronary angiography
por: Bidram, Peyman, et al.
Publicado: (2015)

Do Cardiometabolic Risk Factors Relative Risks Differ for the Occurrence of Ischemic Heart Disease and Stroke?
por: Aalami Harandi, Samaneh, et al.
Publicado: (2016)

Silymarin and diabetic nephropathy
por: Rafieian-Kopaie, Mahmoud, et al.
Publicado: (2012)

Short term high dose atorvastatin for the prevention of contrast-induced nephropathy in patients undergoing computed tomography angiography
por: Sanei, Hamid, et al.
Publicado: (2014)

Cardiovascular risk factors and migraine without aura: A case-control study
por: Harandi, Samaneh Aalami, et al.
Publicado: (2013)

Evaluation of nephroprotection of silymarin on contrast-induced nephropathy in liver cirrhosis patients: A population-based cohort study
por: Kuo, Yu-Jui, et al.
Publicado: (2018)

Intravenous N-acetylcysteine for the PRevention Of Contrast-induced nephropathy – a prospective, single-center, randomized, placebo-controlled trial. The INPROC trial
por: Biernacka-Fiałkowska, Barbara, et al.
Publicado: (2018)

Silymarin in non-cirrhotics with non-alcoholic steatohepatitis: A randomized, double-blind, placebo controlled trial
por: Navarro, Victor J., et al.
Publicado: (2019)

Correction: Silymarin in non-cirrhotics with non-alcoholic steatohepatitis: A randomized, double-blind, placebo controlled trial
por: Navarro, Victor J., et al.
Publicado: (2019)

Omega-3 Supplementation in the Prevention of Contrast Induced Nephropathy in Patients Undergoing Elective Percutaneous Coronary Intervention: A Randomized Placebo-Controlled Trial
por: Foroughinia, Farzaneh, et al.
Publicado: (2019)

Metabolic effect of berberine–silymarin association: A meta‐analysis of randomized, double‐blind, placebo‐controlled clinical trials
por: Fogacci, Federica, et al.
Publicado: (2019)

Remote ischemic preconditioning for prevention of contrast-induced nephropathy – A randomized control trial()
por: Bafna, Akshay Ashok, et al.
Publicado: (2020)

The Prevention of Contrast Induced Nephropathy by Sarpogrelate: a Prospective Randomized Controlled Clinical Trial
por: Ki, You-Jeong, et al.
Publicado: (2019)

Silymarin nanoparticle prevents paracetamol-induced hepatotoxicity
por: Das, Suvadra, et al.
Publicado: (2011)

Silymarin prevents acetaminophen-induced hepatotoxicity in mice
por: Papackova, Zuzana, et al.
Publicado: (2018)

Contrast safety in the cancer patient: preventing contrast-induced nephropathy
por: Heiken, Jay P.
Publicado: (2008)

Sodium Bicarbonate Prevents Contrast-Induced Nephropathy in Addition to Theophylline: A Randomized Controlled Trial
por: Huber, Wolfgang, et al.
Publicado: (2016)

Pentoxifylline for the prevention of contrast-induced nephropathy: systematic review and meta-analysis of randomised controlled trials
por: Wei, Ling, et al.
Publicado: (2021)

A double-blinded randomized controlled trial of silymarin for the prevention of antituberculosis drug-induced liver injury
por: Luangchosiri, Chote, et al.
Publicado: (2015)

The Effectiveness of Silymarin in the Prevention of Anti-tuberculosis Drug-induced Hepatotoxicity: A Randomized Controlled Clinical Trial
por: Talebi, Ali, et al.
Publicado: (2023)

Rationale, design, and baseline characteristics of the Acetylcystein for Contrast-Induced nephropaThy (ACT) Trial: a pragmatic randomized controlled trial to evaluate the efficacy of acetylcysteine for the prevention of contrast-induced nephropathy
Publicado: (2009)

Contrast-induced nephropathy: pharmacology, pathophysiology and prevention
por: Geenen, Remy W. F., et al.
Publicado: (2013)

Preventive Effect of Atorvastatin (80 mg) on Contrast-Induced Nephropathy After Angiography in High-Risk Patients: Double-Blind Randomized Clinical Trial
por: Khosravi, Arezoo, et al.
Publicado: (2016)

Intravenous N-Acetylcysteine for Prevention of Contrast-Induced Nephropathy: A Meta-Analysis of Randomized, Controlled Trials
por: Sun, Zikai, et al.
Publicado: (2013)

The effect of low dose versus standard dose of arterial heparin on vascular complications following transradial coronary angiography: Randomized controlled clinical trial
por: Roghani, Farshad, et al.
Publicado: (2016)

Impact of Supplementation with Omega-3 in the Prevention of Contrast-Induced Nephropathy Following Elective Percutaneous Coronary Intervention in Patients with Chronic Kidney Disease: A Randomized Placebo-Controlled Trial
por: Foroughinia, Farzaneh, et al.
Publicado: (2020)

Adenosine antagonists for prevention of contrast-induced nephropathy: A meta-analysis of randomized controlled trials with trial sequential analysis
por: Zang, Hongbin, et al.
Publicado: (2019)

Comparing right ventricular function and pulmonary artery pressure before and shortly after hemodialysis in patients with end-stage renal disease
por: Najafian, Jamshid, et al.
Publicado: (2015)

Comparison of Normal Saline, Ringer's Lactate, and Sodium Bicarbonate for Prevention of Contrast-induced Nephropathy in Patients with Coronary Angiography: A Randomized Double-blind Clinical Trial
por: Pakfetrat, Maryam, et al.
Publicado: (2019)

Evaluation of N-acetylcysteine for the prevention of contrast-induced nephropathy
por: Richter, Sara K., et al.
Publicado: (2015)

Silymarin, Olibanum, and Nettle, A Mixed Herbal Formulation in the Treatment of Type II Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial
por: Khalili, Nahid, et al.
Publicado: (2017)

The effect of silymarin on liver enzymes and antioxidant status in trauma patients in the intensive care unit: a randomized double blinded placebo-controlled clinical trial
por: Mirzaei, Ehsan, et al.
Publicado: (2021)

Effects of Remote Ischemic Pre-Conditioning to Prevent Contrast-Induced Nephropathy after Intravenous Contrast Medium Injection: A Randomized Controlled Trial
por: Belabbas, Dihia, et al.
Publicado: (2020)

In-vitro and In-vivo Evaluation of Silymarin Nanoliposomes against Isolated Methicillin-resistant Staphylococcus aureus
por: Faezizadeh, Zohreh, et al.
Publicado: (2015)

The protective effects of silymarin nanoemulsion on 5-fluorouracil-induced gastrointestinal toxicity in rats
por: Safarpour, Soheila, et al.
Publicado: (2023)

Can doubling the maintenance dose of clopidogrel prevent from early stent thrombosis after the primary percutaneous coronary intervention?
por: Roghani, Farshad, et al.
Publicado: (2011)

The vasorelaxant effect of simvastatin in isolated aorta from diabetic rats
por: Roghani-Dehkordi, Farshad, et al.
Publicado: (2016)

Effectiveness of N‐Acetylcysteine for the Prevention of Contrast‐Induced Nephropathy: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials
por: Xu, Renfan, et al.
Publicado: (2016)

Preventing contrast-induced nephropathy: problems, challenges and future directions
por: Solomon, Richard
Publicado: (2009)

Prevention of contrast induced nephropathy; a cardiology point of view
por: Hashemi, Mohammad, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_vjp5bs0knf8fnnrpn1n9p0hfq3